Status | Study |
Completed |
Study Name: Nilotinib and LDE225 in the Treatment of Chronic or Accelerated Phase Myeloid Leukemia in Patients Who Developed Resistance to Prior Therapy Condition: Philadelphia Chromosome Positive Chronic Myelogenous Leukemia Date: 2011-10-14 Interventions: Drug: Nilotinib + LDE225 Nilotinib is an aminopyrimidine ATP-competitive inhibitor of the protein tyrosi |
Completed |
Study Name: Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects Condition: Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML) Date: 2011-06-07 Interventions: Drug: Bosutinib 5 clinical 100 |
Terminated |
Study Name: Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Condition: Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia Date: 2011-05-05 Interventions: Drug: entinostat Given PO |
Suspended |
Study Name: Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) Condition: Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) Date: 2010-10-15 Interventions: Drug: Imatinib Mesylate patient will receive Imatinib (Glivec®), 300 mg/m²/day, per oral, in c |
Suspended |
Study Name: Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+) Condition: Chronic Myeloid Leukemia (CML) With Philadelphia Chromosome-positive (Ph+) Date: 2010-10-14 Interventions: Drug: Imatinib Mesylate Patient will receive Imatinib Mesylate, continuous-use, 260 mg/m2/day dose, maxi |
Completed |
Study Name: Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Condition: CML in Chronic Phase Date: 2010-02-01 Interventions: Drug: Nilotinib Nilotinib was supplied by Novartis as 150 mg hard gelatin capsules in bottles. Nilotinib |
Completed |
Study Name: Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Condition: Philadelphia Chromosome Positive Chronic Myelogenous Leukemia i Date: 2010-01-05 Interventions: Drug: Nilotinib 400 mg BID Other Name: AMN107 |
Completed |
Study Name: Rollover Study of BMS-354825 in Patients With CML and Ph+ALL Condition: Chronic Myelogenous Leukemia Philadelphia Chromosome Positive A Date: 2009-12-10 Interventions: Drug: dasatinib Tablet, Oral, (50mg, 70mg or 90mg BID on a continuous daily dosing schedule), allowed to |
Completed |
Study Name: Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion Condition: Philadelphia Chromosome-positive Chronic Myelocytic Leukemia Date: 2009-08-26 Interventions: Procedure: Stem cell transplantation Patients were conditioned with oral busulfan 12mg/kg (days -6 to -4 |
Terminated |
Study Name: Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED) Condition: Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia (CML) Date: 2009-03-05 Interventions: Other: Comparator: Biomarker evaluation Patients on standa |